

EBV Increases Risk of Cancer in the Esophagus; the CBCD Reviews the Medical Evidence

Esophageal cancer occurs when cancer cells develop in the esophagus, a tube-like structure that runs from your throat to your stomach. (1)

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, September 8, 2015 /EINPresswire.com/ --

“Infected with the EBV virus? We recommend taking [Gene-Eden-VIR](#) or [Novirin](#).” – Greg Bennett, CBCD

Most people associate the Epstein Barr Virus (EBV) with infectious mononucleosis (Mono, also known as “the kissing disease”). However, studies are showing that EBV is also linked to esophageal cancer. For example, Dr. Jinru Xue and colleagues wrote in a case study that “Epstein-Barr virus (EBV) has been frequently detected in LELC cells (Lymphoepithelioma carcinoma, a type of cancer) in several organs ... (and) ... appears to be related to tumorigenesis.” (2) In other words, the researchers believe that EBV may be associated with the cause of esophageal cancer. Dr. Xue is from the Department of Thoracic Surgery at the China-Japan Union Hospital of Jilin University, in Changchun, China.

The study mentioned the following case: A 55 year old man presented with “two giant (bleeding) ulcers in the esophagus and stomach, wherein pathological examination and immunohistochemical staining revealed that the two lesions displayed the same form of poorly differentiated carcinoma with a dense



lymphoid stroma and diagnosed as LELC ...” (2) The study concluded that “the association of esophageal LELC and EBV ... all need to be further studied.” (2)

antiviral products was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Gene-Eden-VIR and Novirin formula is effective against EBV and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, "individuals infected with EBV...reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR." (3) The study authors also wrote that, "We observed a statistically significant decrease in the severity, duration, and frequency of symptoms." (3) In addition, this natural antiviral was recently proven to reduce mental and physical fatigue in a post-marketing clinical study that followed FDA guidelines.

Both products can be ordered online on the Gene-Eden-VIR and Novirin websites, here:

<http://www.gene-eden-vir.com>

and

<http://www.novirin.com>

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

EBV chronically infects about 95% of the adult population, with virus usually present in B cells in a latent stage. (4) However, not everyone infected will develop cancer. According to Dr. Polansky, and his book "Microcompetition with Foreign DNA and the Origin of Chronic Disease," people develop cancer when the number of latent viruses passes a certain threshold. One of the reasons for an increase in the number of latent viruses is a weak immune system.

The CBCD offers a free download of Dr. Polansky's book to those who are interested in reading it.

<http://www.cbcd.net/Book.php>

Dr. Fujiwara wrote that people with a chronic EBV infection face a poor outcome. In addition to constant symptoms of Mononucleosis, they can also develop "life-threatening complications including hemophagocytic lymphohistiocytosis (a condition that causes the immune system to attack the body's own tissues), organ failure, and malignant lymphomas (cancer)." (4) Dr. Fujiwara is from the Department of Infectious Diseases, National Research Institute for Child Health and Development in Tokyo, Japan.

What standard treatments are available for EBV infections?

"A few antiviral drugs are available that were shown to inhibit EBV replication in cell culture. These drugs include the acyclic nucleoside analogues aciclovir, ganciclovir, penciclovir, and their respective prodrugs valaciclovir, valganciclovir and famciclovir, the acyclic nucleotide analogues cidofovir and adefovir, and the pyrophosphate analogue foscarnet. However, clinical studies have shown that these drugs are mostly ineffective in humans." (3) There are also natural antiviral products that studies show to be safe and effective in reducing EBV symptoms. Two of these products are Gene-Eden-VIR and

Novirin.

In light of the above information, the CBCD recommends that individuals infected with the latent Epstein Barr Virus (EBV) take Gene-Eden-VIR or Novirin.

Find us on Facebook here: <https://www.facebook.com/GeneEdenVIR>

References:

- (1) WebMD.com - Esophageal Cancer
- (2) Jinru Xue,1,* Haixin Yu,1,* Jidong Yan,1 Na Ren,1 Yi Yang,2 Xueju Wang,3 and Yan Wang1 "Non-Epstein-Barr virus-associated double primary lymphoepithelioma-like carcinoma of the esophagus and stomach: a case report and literature review" Int J Clin Exp Med. 2015; 8(6): 10051–10057
- (3) Polansky H, Itzkovitz E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Pharmacology & Pharmacy, 2013, 4, 1-8 <http://dx.doi.org/10.4236/pp.2013.46A001>
- (4) Fujiwara S1, Kimura H, Imadome K, Arai A, Kodama E, Morio T, Shimizu N, Wakiguchi H. Current research on chronic active Epstein-Barr virus infection in Japan. Pediatr Int. 2014 Apr;56 (2):159-66.

Greg Bennett
CBCD
585-250-9999
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.

